Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11720340 | 0.79 | LMNA (0.40) | TSHRHSD17B10ALOX15TP53LMNA | |
| SCHEMBL22678925 | 0.77 | MAPK1 (0.39) | TSHRHSD17B10ALOX15TP53LMNA | |
| SCHEMBL11714174 | 0.77 | TSHR (0.37) | TSHRHSD17B10ALOX15TP53LMNA | |
| SCHEMBL23900422 | 0.74 | BRD4 (0.54) | TSHRHSD17B10ALOX15TP53LMNA | |
| SCHEMBL12766925 | 0.68 | LMNA (0.40) | TSHRHSD17B10LMNAHTTSMN1; SMN2 | |
| SCHEMBL3806350 | 0.67 | ERN1 (0.42) | TSHRHSD17B10LMNAHTTSMN1; SMN2 | |
| SCHEMBL22408689 | 0.65 | LMNA (0.53) | TSHRHSD17B10ALOX15TP53LMNA | |
| SCHEMBL13543195 | 0.64 | HTT (0.73) | LMNAHTTSMN1; SMN2L3MBTL1POLB | |
| SCHEMBL17254245 | 0.64 | ERN1 (0.37) | TSHRHSD17B10ALOX15LMNAHTT | |
| SCHEMBL12775686 | 0.64 | KMT2A (0.39) | TSHRHSD17B10LMNAHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731967-B2 | Inhibitors of TRIM33 and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731967-B2 | Inhibitors of TRIM33 and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731967-B2 | Inhibitors of TRIM33 and methods of use | TRIM33, TRIM28, TRIM4 | TSHR 4671/4885HSD17B10 2418/4885ALOX15 4161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.